DMP Dermapharm Holding SE

36.69USD33.45 EUR · XETRA-1.76%Mkt Cap: 1.82B USDP/E: 13.27

Dermapharm Holding SE, together with its subsidiaries, manufactures and sells off-patent branded pharmaceutical products in Germany, Italy, France, Austria, Switzerland, Spain, Portugal, the Netherlands, Croatia, Poland,…

Institutional holders11 on file

Key Statistics

Company
Market Cap1.82B USD
Enterprise Value2.95B USD
Revenue (TTM)1.30B USD
Gross Profit858.72M USD
Net Income (TTM)145.23M USD
Revenue/Share25.07 USD
Last Price36.69 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees3.5K
CountryDE
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINDE000A2GS5D8
Valuation
P/E (Trailing)13.27
P/E (Forward)11.31
PEG—
EV/EBITDA8.76
EV/Revenue2.28
P/S1.40
P/B2.96
EPS (TTM)2.76 USD
EPS (Forward)3.24 USD
52W Range
36.302% of range56.92
52W High56.92 USD
52W Low36.30 USD
Profitability
Gross Margin67.21%
Oper. Margin19.92%
EBITDA Margin25.99%
Profit Margin11.37%
ROE19.07%
ROA6.06%
ROIC10.57%
ROCE12.33%
Growth
Revenue Growth-0.50%
Earnings Growth-33.30%
Cash Flow & Leverage
Operating CF251.33M USD
CapEx (TTM)46.19M USD
FCF Margin9.71%
FCF Yield6.92%
Net Debt1.13B USD
Net Debt/EBITDA3.37
Net Debt/FCF9.02
Balance Sheet
Debt/Equity1.52
Current Ratio1.79
Quick Ratio0.67
Book Value/Sh12.41 USD
Cash/Share2.59 USD
Dividends
Fwd Div Rate0.97 USD
Trail. Div Rate0.97 USD
Div. Yield2.51%
5Y Avg Yield2.49%
Payout Ratio34.92%
Ex-Div DateJun 29, 2026
Pay Date—
Analyst Consensus
Rating2.0 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)55.94 USD
Upside (mean)+52.5%
Target Range48.26 USD – 65.81 USD
48.26+52.5% to mean65.81
# Analysts4
Ownership
Shares Out.49.54M
Float6.48M
Insiders89.30%
Institutions6.57%
Technical
SMA 5041.81 (-12.2%)
SMA 20046.27 (-20.7%)
Beta0.85
S&P 52W Chg12.00%
Avg Vol (30d)22.27K
Avg Vol (10d)35.98K
Technical Indicators
RSI (14)25.7
MACD-1.0928
MACD Signal-0.6041
MACD Hist.-0.4886
BB Upper44.96 USD
BB Middle40.94 USD
BB Lower36.92 USD
BB Width19.63%
ATR (14)1.126 USD
Vol Ratio (20d)1.52x

About Dermapharm Holding (ETR: DMP)

›

Dermapharm Holding (ETR: DMP) is listed on Xetra (Frankfurt), where its shares trade in EUR. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 3,503 employees.

The shares were at 33.45 EUR on 19 November 2026, down 3.7% over 52 weeks. Its 52-week range is 33.10 EUR to 51.90 EUR: the price is 35.5% below the high and 1.1% above the low.

At a market capitalisation of 1.66B EUR, it trades at 13.3 times trailing earnings and 11.3 times forward earnings. The median trailing P/E of its 17 largest Drug Manufacturers - Specialty & Generic peers is 24.7, a discount of 46% for DMP. It pays a dividend yielding 2.51% (it pays out 35% of its earnings), against a median of 1.90% among the dividend payers in that peer group.

Dermapharm Holding reports return on equity of 19.1%, an operating margin of 19.9% and revenue down 0.5% year over year.

Its debt exceeds its cash by 1.03B EUR, a debt-to-equity ratio of 1.52. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 4 analysts cover the stock, with an average rating of Buy; their mean price target of 51.00 EUR is 52.5% above the current price. The next earnings report is expected on 25 March 2027.